FR2479228A1 - CEPHAPIRINE SALTS WITH AMINO ACIDS - Google Patents

CEPHAPIRINE SALTS WITH AMINO ACIDS Download PDF

Info

Publication number
FR2479228A1
FR2479228A1 FR8106002A FR8106002A FR2479228A1 FR 2479228 A1 FR2479228 A1 FR 2479228A1 FR 8106002 A FR8106002 A FR 8106002A FR 8106002 A FR8106002 A FR 8106002A FR 2479228 A1 FR2479228 A1 FR 2479228A1
Authority
FR
France
Prior art keywords
cephapirin
cephapirine
salt
cooh
arginine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR8106002A
Other languages
French (fr)
Other versions
FR2479228B1 (en
Inventor
Marco Falciani
Renato Broggi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dobfar SpA
Original Assignee
Dobfar SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dobfar SpA filed Critical Dobfar SpA
Publication of FR2479228A1 publication Critical patent/FR2479228A1/en
Application granted granted Critical
Publication of FR2479228B1 publication Critical patent/FR2479228B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D501/00Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/207-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/247-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/26Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
    • C07D501/34Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings

Abstract

SELS DE CEPHAPIRINE AVEC UN AMINO-ACIDE SELECTIONNE DANS LE GROUPE COMPOSE DE LA L-LYSINE, LA L-ARGININE ET L'ACETYLCYSTEINE. CES SELS SONT OBTENUS EN FAISANT REAGIR UNE SOLUTION AQUEUSE DE CEPHAPIRINE AVEC UNE SOLUTION AQUEUSE D'UN AMINO-ACIDE OU SON DERIVE, SELECTIONNE DANS LE GROUPE COMPOSE DE LA L-LYSINE, LA L-ARGININE ET L'ACETYLCYSTEINE. POUR ISOLER LE SEL, LA SOLUTION AQUEUSE EST SOUMISE A LA LYOPHILISATION.SALTS OF CEPHAPIRINE WITH AN AMINO ACID SELECTED FROM THE GROUP CONSISTING OF L-LYSINE, L-ARGININE AND ACETYLCYSTEINE. THESE SALTS ARE OBTAINED BY REACTING AN AQUEOUS SOLUTION OF CEPHAPIRINE WITH AN AQUEOUS SOLUTION OF AN AMINO ACID OR ITS DERIVATIVE, SELECTED FROM THE GROUP CONSISTING OF L-LYSINE, L-ARGININE AND ACETYLCYSTEINE. TO ISOLATE THE SALT, THE AQUEOUS SOLUTION IS SUBJECT TO LYOPHILIZATION.

Description

L'invention se rapporte à de nouveaux sels de céphapirine avec des amino-The invention relates to novel cephapirin salts with amino

acides, ces sels ayant uneacids, these salts having a

activité antibiotique. La céphapirine est un antibioti-  antibiotic activity. Cephapirin is an antibiotic

que bien connu, décrit dans le brevet américain No 3 422 100 et la demande de brevet japonais publiée  as well known, described in US Patent No. 3,422,100 and published Japanese patent application

sous le No 44-26107.under No. 44-26107.

La céphapirine est habituellement administrée  Cephapirin is usually administered

par voie parentérale sous la forme de son sel de sodium.  parenterally in the form of its sodium salt.

Il est bien connu que les sels de sodium de ce  It is well known that the sodium salts of this

type d'antibiotique et, en particulier, de la céphapiri-  type of antibiotic and, in particular, cephapirin

ne, sont d'administration douloureuse par injection.  no, are painful administration by injection.

L'invention se propose de fournir de nouveaux sels de céphapirine qui sont injectables sans induire de  The invention proposes to provide new cephapirin salts which are injectable without inducing

réaction douloureuse lorsqu'on les administre.  painful reaction when administered.

Elle concerne encore des sels de céphapirine qui accroissent l'absorption de la substance antibiotique et  It also relates to cephapirin salts which increase the absorption of the antibiotic substance and

qui, lorsqu'ils sont absorbés par l'organisme, sont capa-  which, when absorbed by the organism, are capable of

ble de joindre à l'activité antibiotique propre à la céphapirine leur propre activité spécifique, qui peut  the cephapirin-specific antibiotic activity of their own specific activity, which may be

avoir un certain intérêt du point de vue pharmacologique.  have some interest from a pharmacological point of view.

Ces résultats sont obtenus par salification de la céphapirine avec un amino-acide sélectionné dans le  These results are obtained by salification of cephapirin with an amino acid selected from

groupe composé de la L-lysine, la L-arginine et l.acétyl-  group consisting of L-lysine, L-arginine and acetyl-

cystéine. Pour obtenir cette salification, on fait réagir la céphapirine en solution aqueuse et à la température ambiante avec une solution aqueuse d'un amino-acide ou de son dérivé, sélectionné dans le groupe composé de la L-lysine, la L-arginine et l'acétylcistéine, le sel de  cysteine. To obtain this salification, cephapirin is reacted in aqueous solution and at room temperature with an aqueous solution of an amino acid or its derivative, selected from the group consisting of L-lysine, L-arginine and l-arginine. acetylcistine, the salt of

céphapirine étant isolé de la solution aqueuse par lyo-  cephapirin being isolated from the aqueous solution by

philisation.philisation.

L'invention sera mieux comprise à l'aide de la  The invention will be better understood using the

description ci-après d'un procédé de préparation des trois  description below of a process for preparing the three

sels qui font l'objet de l'invention, donné à titre  salts which are the subject of the invention, given as

d'exemple purement illustratif.purely illustrative example.

Exemple 1Example 1

Lysinate de céphapirine de formuleCephapirin Lysinate Formula

- S -CH -XH- S -CH -XH

oN CHP2COCH3oN CHP2COCH3

COQH. H2N-(CH2) 4-CH-COOHCOQH. H2N- (CH2) 4-CH-COOH

H2H2

On introduit dans un flacon de réaction de l'eau bidistillée (500 ml) et de la céphapirine sous la forme acide (42,3 g, 0,1 mole); on mesure le pH et on constate qu'il est à 3,5. On ajoute une solution aqueuse de base Llysine à 50 contenant 14,6 g (0,1 mole) de base L-lysine; le mélange est maintenu sous agitation pendant 1 heure à 0 C. La dissolution complète est obtenue et le pH est élevé à 8. On ajoute du carbone décolorant (1,5 g) à la solution obtenue, que l'on filtre à travers des plaques de filtrage, et que l'on verse dans une coupelle  Two-distilled water (500 ml) and cephapirin in the acid form (42.3 g, 0.1 mole) were added to a reaction flask; the pH is measured and it is found that it is at 3.5. A 50 Lysine aqueous base solution containing 14.6 g (0.1 mole) of L-lysine base is added; the mixture is stirred for 1 hour at 0 C. Complete dissolution is obtained and the pH is raised to 8. Bleaching carbon (1.5 g) is added to the resulting solution, which is filtered through filters. filter plates, and poured into a cup

jusqu'à obtenir une couche de 1 cm d'épaisseur. La solu-  until you get a 1 cm thick layer. The solution

tion est alors congelée à -40 C et lyophilisée. Après 24 heures, la matière obtenue est enlevée et tamisée. On  The mixture is then frozen at -40 ° C. and freeze-dried. After 24 hours, the resulting material is removed and sieved. We

obtient du lysinate de céphapirine (54 g).  obtains cephapirine lysinate (54 g).

KF: 1,5%KF: 1.5%

TLC: produit unique Z- 7D (c = 1, H20: + 127   TLC: single product Z-7D (c = 1, H20: + 127

Titre microbiologique = 730 mcg/mg comme la céphapi-  Microbiological titre = 730 mcg / mg as cephapid

rine sous la forme d'acide.in the form of acid.

- 3 -- 3 -

Exemple 2Example 2

Sel d'arginine de céphapirine ayant la formule  Cephapirine arginine salt having the formula

N 5"-S-CH2- CO-NHN 5 "-S-CH 2 -CO-NH

CH2OCOCH3CH2OCOCH3

COOH. H2N\ (C H2COOH. H2N \ (C H2

C-NH-(CH 2)3-H-COOHC-NH- (CH 2) 3 -H-COOH

NH On introduit dans un flacon de réaction à 0 C, de l'eau bidistillée (450 ml) et de la céphapirine sous  A double-distilled water (450 ml) and cephapirin were added to a reaction flask at 0 ° C.

la forme d'acide (42,3 g, 0,1 mole); le pH est de 3,5.  the acid form (42.3 g, 0.1 mole); the pH is 3.5.

On ajoute à 0 C, une solution aqueuse à 10% de  At 0 ° C., a 10% aqueous solution of

L-arginine (210 ml) contenant 21 g de L-arginine.  L-arginine (210 ml) containing 21 g of L-arginine.

Le mélange de réaction est maintenu à 0 C pen-  The reaction mixture is maintained at 0 C

dant 30 minutes; le pH est élevé à 8,5. On ajoute du car-  30 minutes; the pH is raised to 8.5. We add car-

bone décolorant (5 g) à la solution obtenue, qui est filtrée à travers des plaques de filtrage et versée dans  bleaching bone (5 g) to the resulting solution, which is filtered through filter plates and poured into

une coupelle jusqu'à obtenir une couche de 1 cm d'épais-  cup until a layer of 1 cm thick is

seur. Après pré-congélation à -45 C, on commence la lyo-  sor. After pre-freezing at -45 C, we begin the

philisation. Elle se termine après 24 heures, la matière obtenue étant enlevée et tamisée; on obtient du sel  philisation. It ends after 24 hours, the material obtained being removed and sieved; we get salt

d'arginine de céphapirine (55 g).arginine of cephapirin (55 g).

KF: 1,2%KF: 1.2%

TLC: produit simple Zq7D (c = 1, H20): + 120   TLC: simple product Zq7D (c = 1, H20): + 120

Titre microbiologique: 687 mcg/g comme la céphapi-  Microbiological titre: 687 mcg / g, like cephapins

rine sous la forme d'acide.in the form of acid.

- 4 -- 4 -

Exemple 3Example 3

Acétylcystéinate de céphapirine ayant la formule  Cephapirin acetylcysteate having the formula

HS -C2 -CH-COO. >-S -CHH2-CO-NH H2 3  HS -C2 -CH-COO. > -S-CHH2-CO-NH H2 3

NH-COCH3 0NH-COCH3 0

COOH On introduit dans un flacon de réaction de l'eau (500 ml) et de la céphapirine sous la forme d'acide (42, g 0,1 mole). Après refroidissement à 0 C, on ajoute  COOH Water (500 ml) and cephapirin in the form of acid (42.0 g 0.1 mol) are introduced into a reaction flask. After cooling to 0 C, add

une solution aqueuse contenant 16,3 g (0,1 mole) d'acétyl-  an aqueous solution containing 16.3 g (0.1 mol) of acetyl

cistéine. La dissolution complète est obtenue; le pH cor-  cistéine. Complete dissolution is obtained; the correct pH

respondant est 2,1. On laisse le mélange réagir pendant 1 heure; on ajoute alors 3 g de carbone. La solution obtenue est filtrée à travers des plaques de filtrage, versée dans une coupelle jusqu'à obtenir une couche de  respondent is 2.1. The mixture is allowed to react for 1 hour; 3 g of carbon are then added. The solution obtained is filtered through filter plates, poured into a cup until a layer of

1 cm d'épaisseur et soumise à une pré-congélation.  1 cm thick and pre-frozen.

A -40 C, la solution est complètement congelée et est lyophilisée. La lyophilisation est terminée en 36 heures. La matière obtenue est tamisée et on obtient  At -40 ° C, the solution is completely frozen and lyophilized. Lyophilization is complete in 36 hours. The obtained material is sieved and we obtain

de l'acétylcystéinate de céphapirine (55,6 g).  cephapirin acetylcysteate (55.6 g).

KF: 1%KF: 1%

TLC: produit unique t-D (c: 1, H20): + 118 Titre microbiologique: 707 mcg/mg comme la  TLC: single product t-D (c: 1, H20): + 118 microbiological title: 707 mcg / mg as the

céphapirine sous la forme d'acide.cephapirin in the form of acid.

- 5 -- 5 -

Claims (5)

REVENDICATIONS -CLAIMS - 1. Sel de céphapirine avec un amino-acide sélectionnê dans le groupe composé de la L-lysine, la  1. Cephapirin salt with an amino acid selected from the group consisting of L-lysine, L-arginine et l'acétylcystéine.L-arginine and acetylcysteine. 2. Sel de céphapirine qui est un lysinate de céphapirine ayant la formule  2. Cephapirine salt which is a cephapirine lysinate having the formula \,\ S-CH -CONH - S\, \ S-CH -CONH - S 2- CHv C 20CO0H32- CH 2 C 20 COOH COOH. H2N-(CH2) 4-CH-COOH  COOH. H2N- (CH2) 4-CH-COOH 3. Sel de céphapirine qui est un-sel d'arginine de céphapirine ayant la formule S  3. Cephapirin salt which is a salt of cephapirin arginine having the formula S N -S-CH 2-C0-NEF(IC2C0HN-S-CH 2 -CO-NEF (IC 2 COH N9 S CH2 > e CH 2OCOCH3N9 S CH2> e CH 2OCOCH3 COOH. H2 N NEH2COOH. H2 N NEH2 sC-NH-(CH2) 3-CH-COOH NHsC-NH- (CH2) 3-CH-COOH NH 4. Sel de céphapirine qui est un acétylcystéina-  4. Cephapirine salt which is an acetylcysteine te de céphapirine ayant la formulecephapirin with the formula SS HS-CH -CH-COOH. N -S-CHE-CO-NH SHS-CH-CH-COOH. N-S-CHE-CO-NH S 2 1 2 N CH2OCOCH32 1 2 N CH2OCOCH3 NH-COCH3 COONH-COCH3 COO 2479Z282479Z28 - 6 -  - 6 - 5. Procédé de préparation d'un sel de céphapirine5. Process for preparing a cephapirine salt selon l'une des revendications de 1 à 4, caractérisé en ce  according to one of claims 1 to 4, characterized in that que l'on fait réagir de la céphapirine à la température ambiante avec une solution aqueuse d'un amino-acide ou son dérivé, sélectionné dans le groupe composé de la L-lysine, la L-arginine et l'acétylcystéine, le sel de céphapirine  cephapirin is reacted at room temperature with an aqueous solution of an amino acid or its derivative, selected from the group consisting of L-lysine, L-arginine and acetylcysteine, the salt of cephapirin étant isolé de la solution aqueuse par lyophilisation.  being isolated from the aqueous solution by lyophilization.
FR8106002A 1980-04-01 1981-03-25 CEPHAPIRINE SALTS WITH AMINO ACIDS Granted FR2479228A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT21097/80A IT1141406B (en) 1980-04-01 1980-04-01 SALTS OF CEPHAPIRINE WITH AMINO ACIDS

Publications (2)

Publication Number Publication Date
FR2479228A1 true FR2479228A1 (en) 1981-10-02
FR2479228B1 FR2479228B1 (en) 1985-04-26

Family

ID=11176688

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8106002A Granted FR2479228A1 (en) 1980-04-01 1981-03-25 CEPHAPIRINE SALTS WITH AMINO ACIDS

Country Status (10)

Country Link
JP (1) JPS56152490A (en)
CA (1) CA1133471A (en)
CH (1) CH651050A5 (en)
DE (1) DE3110190A1 (en)
FR (1) FR2479228A1 (en)
GB (1) GB2072675B (en)
IL (1) IL62254A (en)
IT (1) IT1141406B (en)
NL (1) NL8101274A (en)
YU (1) YU82781A (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1242699A (en) * 1985-02-01 1988-10-04 Bristol-Myers Company Cefbuperazone and derivatives thereof
US6566401B2 (en) * 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
CN102351885B (en) * 2011-08-19 2012-08-22 深圳立健药业有限公司 Method for preparing cefuroxime-L-arginine hydrate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1580837A (en) * 1967-01-05 1969-09-12
FR2220533A1 (en) * 1973-03-08 1974-10-04 Gallardo Antonio Sa

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5089517A (en) * 1973-12-18 1975-07-18
JPS51125714A (en) * 1975-02-19 1976-11-02 Banyu Pharmaceut Co Ltd A process for preparing salts of an antibacterial compound
JPS557434A (en) * 1978-06-30 1980-01-19 Matsushita Electric Works Ltd Preparation of woody cement board

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1580837A (en) * 1967-01-05 1969-09-12
FR2220533A1 (en) * 1973-03-08 1974-10-04 Gallardo Antonio Sa

Also Published As

Publication number Publication date
GB2072675A (en) 1981-10-07
DE3110190A1 (en) 1982-02-18
IT8021097A0 (en) 1980-04-01
CA1133471A (en) 1982-10-12
YU82781A (en) 1983-09-30
IL62254A (en) 1984-09-30
IL62254A0 (en) 1981-05-20
CH651050A5 (en) 1985-08-30
GB2072675B (en) 1983-12-07
FR2479228B1 (en) 1985-04-26
IT1141406B (en) 1986-10-01
JPS56152490A (en) 1981-11-26
NL8101274A (en) 1981-11-02

Similar Documents

Publication Publication Date Title
FR2623498A1 (en) NOVEL ENANTIOMERIC COMPOUNDS DERIVED FROM AMINO ACIDS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS
JPS581105B2 (en) Optically active amino acid-mandelic acid complex and method for producing the same
Myers et al. A one-step synthesis of pseudoephedrine glycinamide, a versatile precursor for the synthesis of α-amino acids
FR2479228A1 (en) CEPHAPIRINE SALTS WITH AMINO ACIDS
EP0530887A1 (en) Organic nitrates, processes for their preparation and their use in the treatment of cardiovascular diseases
BE1011326A5 (en) Process for preparing a crystalline form therapeutically active and glucosamine sulphate and glucosamine sulphate obtained.
FR2591226A1 (en) AROMATIC SULFONIC ACID SALTS OF NE-TRIFLUOROACETYL-L-LYSYL-L-PROLINE
WO2000071526A1 (en) Gadolinium complex tetramides and use in medical imaging
SU504491A3 (en) The method of obtaining derivatives of penicillin
FR2504526A1 (en) AMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTI-COMPLEMENT AGENTS CONTAINING THEM
EP0279716B1 (en) Process for the n-omega-trifluoroacetylation of alpha, omega-saturated aliphatic diamino-monocarboxylic acids
FR2777889A1 (en) New octahydro-6,10-dioxo-6H-pyridazino(1,2-a)-1,2-diazepin-1-carboxy lic acid derivatives useful as intermediates for pharmaceuticals
US3488379A (en) Optically active salt complexes of carnitine nitrile hydroxide and n-acryl glutamic acids and their preparation
US3637804A (en) Phenylalanine derivatives and preparation thereof
WO1983000146A1 (en) New derivatives of dipeptides, method for the preparation thereof and utilization thereof as drugs
FR2479226A1 (en) CEPHADROXYL SALTS WITH AMINO ACIDS
Gaudry Study on the synthesis of valine by the Strecker method
CH410900A (en) Process for preparing new nitrogen mustards
EP0092380B1 (en) Antiallergic 4h-furo(3,2-b)indoles and their production
JP3400105B2 (en) Optically active sulfonic acid derivative and production method thereof
FR2478629A1 (en) 2-CYANO-ETHYL-2- (N-BENZOYLAMINO) ALKANOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION
CA1098911A (en) N-(1'-ethyl 2'-oxo 5'-pyrrolidinyl methyl) benzamids, preparation process and use as behaviour modifiers
SU939443A1 (en) Process for producing 2-phenyl-4(beta-carbmethoxypropionyl) oxazolinone-5
JPS6134424B2 (en)
SE8205563D0 (en) PROCESS FOR THE PREPARATION OF VINCAMINIC ACID ESTERS

Legal Events

Date Code Title Description
ST Notification of lapse